CAPTRUST Financial Advisors
FULC icon

CAPTRUST Financial Advisors’s Fulcrum Therapeutics FULC Stock Holding History

CAPTRUST Financial Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-72
Closed – – 2804
2022
Q2 		$0 Buy
+72
New +$704 ﹤0.01% 5000

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

CAPTRUST Financial Advisors's FULC Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Fulcrum Therapeutics (FULC) in Q3 2022, closing a stake of 72 shares.

CAPTRUST Financial Advisors first reported a position in FULC in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 105 funds tracked by Wall St. Rank hold FULC as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Fulcrum Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 72 Fulcrum Therapeutics shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Fulcrum Therapeutics in Q2 2022 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Fulcrum Therapeutics position peaked at $0 in Q2 2022.
  • 105 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.